Yuichiro Arima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuichiro Arima has a total of 333 co-authors. Here are the top co-authors by number of shared publications:
- Kenichi Tsujita
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University , Kumamoto
90 shared publications - Azusa Tanaka
Department of Human Genetics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
76 shared publications - Jun-Ichirou Yasunaga
Department of Hematology, Rheumatology and Infectious Diseases Kumamoto University Hospital Kumamoto Japan
76 shared publications - Koichi Ohshima
Department of Pathology, Kurume University School of Medicine, Kurume, Japan
76 shared publications - Kosuke Toyoda
Department of Hematology, Rheumatology and Infectious Diseases, Faculty of Life Sciences, Kumamoto University
76 shared publications - Masao Matsuoka
Kumamoto University
76 shared publications
Latest Publications
- Open Access
- 17 November 2026
- Published by Elsevier in Molecular Metabolism
Acute fasting-induced maternal ketogenesis determines fetal ketone body availability during late gestation
- 17 November 2026
- Published by Elsevier in Molecular Metabolism
Open AccessAcute fasting-induced maternal ketogenesis determines fetal ketone body availability during late gestation
- 19 October 2026
- Published by Oxford University Press (OUP) in American Journal of Hypertension
Amlodipine and nifedipine associations with B-type natriuretic peptide in women with hypertension and heart failure with preserved ejection fraction
Background: Calcium channel blockers (CCBs) are frequently prescribed to manage hypertension in patients with heart failure with preserved ejection fraction (HFpEF). However, whether individual dihydropyridine agents exert uniform class effects on myocardial wall stress remains unclear. Methods: This retrospective, single-center observational study analyzed 465 consecutive patients with hypertension and HFpEF (354 women and 111 men) evaluated at Kumamoto Kinoh Hospital between May 2012 and July 2018. Multivariable linear regression models assessed associations between individual dihydropyridine CCBs (amlodipine vs nifedipine) and plasma log-transformed B-type natriuretic peptide (lnBNP) levels. Results: In multiple imputation models among women, adjusted differences in lnBNP relative to no-CCB were 0.236 (95% CI, 0.031 to 0.441) for nifedipine and −0.118 (95% CI, −0.273 to 0.037) for amlodipine. Direct linear contrasts in women confirmed lower lnBNP levels with amlodipine than with nifedipine (adjusted difference, −0.355; 95% CI, −0.562 to −0.147). In men, the corresponding amlodipine-vs-nifedipine difference was −0.051 (95% CI, −0.697 to 0.595; P = .876). The formal sex-by-drug interaction contrast in complete-case analysis yielded an adjusted difference of −0.424 (95% CI, −1.055 to 0.208; P = .188), with male precision constrained by sample size (7 male nifedipine users). Conclusions: In women with hypertension and heart failure with preserved ejection fraction, amlodipine use was associated with lower adjusted ln(BNP) levels than nifedipine use. These observational findings challenge the assumption of an interchangeable dihydropyridine class effect on myocardial wall stress, suggesting that individual pharmacological profiles—rather than uniform class-level equivalence—warrant attention in clinical evaluations.
- 19 October 2026
- Published by Oxford University Press (OUP) in American Journal of Hypertension
Amlodipine and nifedipine associations with B-type natriuretic peptide in women with hypertension and heart failure with preserved ejection fraction
Background: Calcium channel blockers (CCBs) are frequently prescribed to manage hypertension in patients with heart failure with preserved ejection fraction (HFpEF). However, whether individual dihydropyridine agents exert uniform class effects on myocardial wall stress remains unclear. Methods: This retrospective, single-center observational study analyzed 465 consecutive patients with hypertension and HFpEF (354 women and 111 men) evaluated at Kumamoto Kinoh Hospital between May 2012 and July 2018. Multivariable linear regression models assessed associations between individual dihydropyridine CCBs (amlodipine vs nifedipine) and plasma log-transformed B-type natriuretic peptide (lnBNP) levels. Results: In multiple imputation models among women, adjusted differences in lnBNP relative to no-CCB were 0.236 (95% CI, 0.031 to 0.441) for nifedipine and −0.118 (95% CI, −0.273 to 0.037) for amlodipine. Direct linear contrasts in women confirmed lower lnBNP levels with amlodipine than with nifedipine (adjusted difference, −0.355; 95% CI, −0.562 to −0.147). In men, the corresponding amlodipine-vs-nifedipine difference was −0.051 (95% CI, −0.697 to 0.595; P = .876). The formal sex-by-drug interaction contrast in complete-case analysis yielded an adjusted difference of −0.424 (95% CI, −1.055 to 0.208; P = .188), with male precision constrained by sample size (7 male nifedipine users). Conclusions: In women with hypertension and heart failure with preserved ejection fraction, amlodipine use was associated with lower adjusted ln(BNP) levels than nifedipine use. These observational findings challenge the assumption of an interchangeable dihydropyridine class effect on myocardial wall stress, suggesting that individual pharmacological profiles—rather than uniform class-level equivalence—warrant attention in clinical evaluations.
- Open Access
- 5 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Suppressing glutamate dehydrogenase guides hematopoietic stem cell divisions into self-renewal
Hematopoietic stem cells (HSCs) self-renew to expand their pool but often differentiate upon division. Thus, it remains unclear how HSCs maintain their stemness during or after division. Here, we show that the suppression of glutamate dehydrogenase (Glud1), a key enzyme responsible for glutamate (Glu) catabolism, supports the maintenance of HSCs during division. We find that self-renewing mouse HSCs during hematopoietic regeneration exhibited lower intracellular Glu levels compared to HSCs differentiating during ex vivo culture. We therefore focus on the negative regulation of Glu catabolic reactions as a candidate factor to maintain HSCs during division, and find that treatment with the Glud1 inhibitor, R162, maintains a subset of HSCs that would otherwise differentiate during division under normal culture conditions. This treatment successfully results in an approximately 500-fold expansion of functional mouse HSCs that maintain expression pattern of conventional stem cell markers over a 30-day culture period. Importantly, this positive effect of Glud1 inhibition is independent of suppressing cell divisions and dependent on robust JAK2-STAT signaling. Overall, our findings propose that Glud1 inhibition, coupled with robust JAK2–STAT signaling, characterizes a functional HSC state during division, enabling ex vivo expansion of mouse HSCs under conventional culture conditions.
- 5 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessSuppressing glutamate dehydrogenase guides hematopoietic stem cell divisions into self-renewal
Hematopoietic stem cells (HSCs) self-renew to expand their pool but often differentiate upon division. Thus, it remains unclear how HSCs maintain their stemness during or after division. Here, we show that the suppression of glutamate dehydrogenase (Glud1), a key enzyme responsible for glutamate (Glu) catabolism, supports the maintenance of HSCs during division. We find that self-renewing mouse HSCs during hematopoietic regeneration exhibited lower intracellular Glu levels compared to HSCs differentiating during ex vivo culture. We therefore focus on the negative regulation of Glu catabolic reactions as a candidate factor to maintain HSCs during division, and find that treatment with the Glud1 inhibitor, R162, maintains a subset of HSCs that would otherwise differentiate during division under normal culture conditions. This treatment successfully results in an approximately 500-fold expansion of functional mouse HSCs that maintain expression pattern of conventional stem cell markers over a 30-day culture period. Importantly, this positive effect of Glud1 inhibition is independent of suppressing cell divisions and dependent on robust JAK2-STAT signaling. Overall, our findings propose that Glud1 inhibition, coupled with robust JAK2–STAT signaling, characterizes a functional HSC state during division, enabling ex vivo expansion of mouse HSCs under conventional culture conditions.
- Open Access
Hepatic Ketogenesis Attenuates Cardiac Hypertrophy via Metabolic Reprogramming
Background: Heart failure with preserved ejection fraction (HfpEF) is increasingly recognized as a multisystem disorder linked to the cardiovascular-kidney-metabolic (CKM) syndrome. While the falling heart undergoes metabolic reprogramming, the interorgan crosstalk regulating myocardial substrate preference in HFpEF remains elusive. We aimed to clarify the role of systemic and local ketogenesis in the pathogenesis of cardiac hypertrophy and HFpEF. Methods: A mouse model of HFpEF was employed using a high-fat diet combined with NG-Nitro-L-arginine methyl ester hydrochloride (L-NAME). Cardiac hypertrophy and systemic metabolic profiling including ketogenesis were evaluated. To dissect the role of site-specific ketogenesis, we generated inducible cardiomyocyte-specific ( Hmgcs2 ΔiCM ) and hepatocyte-specific ( Hmgcs2 ΔHep ) knockout mice of HMG-CoA synthase 2 ( Hmgcs2 ), deficient in the rate-limiting enzyme for ketogenesis. Cardiomyocyte -specific nuclei were isolated for transcriptomic (RNA-seq) and in vitro assays in H9C2 cells were used to elucidate molecular mechanisms. Results: The HFpEF model successfully exhibited diastolic dysfunction, impaired exercise capacity and cardiac hypertrophy with elevated circulating ketone body concentration. Myocardial metabolomics and snRNA-seq identified a profound metabolic shift characterized by the accumulation of long-chain fatty acids and Krebs cycle intermediates, coupled with the transcriptional downregulation of insulin signaling and fatty acid degradation pathways. Although circulating ketone body level was upregulated, Hmgcs2 ΔiCM mice showed no exacerbation of the HFpEF phenotype. In contrast, Hmgcs2 ΔHep mice exhibited significantly aggravated cardiac hypertrophy (HW/TL; Hmgcs2 flox : 7.41 ± 0.87: Hmgcs2 ΔHep : 8.29 ± 0.73; p = 0.0154). Mechanistically, hepatic ketogenesis was required to maintain circulating beta-hydroxybutyrate (BHB) levels, which directly modulated cardiomyocyte metabolism. BHB acted as a metabolic signal to dampen fatty acid overload and facilitate glucose utilization. Conclusions: Our study identifies a critical "liver-heart axis" where hepatic ketogenesis serves as an essential regulator of myocardial metabolic resilience. Impaired hepatic ketogenesis creates a metabolic mismatch that drives pathological cardiac remodeling. These findings highlight the liver as a therapeutic target within the CKM syndrome framework, suggesting that restoring the hepato-cardiac metabolic bridge may ameliorate HFpEF progression. What is New?: This study identifies a novel liver–adipose–heart axis that governs myocardial metabolic resilience during the development of heart failure with preserved ejection fraction (HFpEF). We demonstrate that while both the liver and heart upregulate ketogenesis under metabolic stress, only hepatic ketogenesis—and not cardiac-intrinsic ketogenesis—is essential for mitigating pathological cardiac remodeling. Mechanistically, liver-derived β -hydroxybutyrate acts as a critical endocrine signal that dampens fatty acid oxidation and facilitates myocardial glucose utilization. What Are the Clinical Implications?: Our findings highlight the liver as a central therapeutic target within the cardiovascular–kidney–metabolic (CKM) syndrome framework, where hepatic metabolic failure directly drives cardiac dysfunction. Restoring the hepato-cardiac metabolic bridge, through either hepatic-targeted therapies or ketone body supplementation, represents a promising strategy to enhance myocardial metabolic flexibility and ameliorate HfpEF in patients with multi-organ metabolic disorders.
Open AccessHepatic Ketogenesis Attenuates Cardiac Hypertrophy via Metabolic Reprogramming
Background: Heart failure with preserved ejection fraction (HfpEF) is increasingly recognized as a multisystem disorder linked to the cardiovascular-kidney-metabolic (CKM) syndrome. While the falling heart undergoes metabolic reprogramming, the interorgan crosstalk regulating myocardial substrate preference in HFpEF remains elusive. We aimed to clarify the role of systemic and local ketogenesis in the pathogenesis of cardiac hypertrophy and HFpEF. Methods: A mouse model of HFpEF was employed using a high-fat diet combined with NG-Nitro-L-arginine methyl ester hydrochloride (L-NAME). Cardiac hypertrophy and systemic metabolic profiling including ketogenesis were evaluated. To dissect the role of site-specific ketogenesis, we generated inducible cardiomyocyte-specific ( Hmgcs2 ΔiCM ) and hepatocyte-specific ( Hmgcs2 ΔHep ) knockout mice of HMG-CoA synthase 2 ( Hmgcs2 ), deficient in the rate-limiting enzyme for ketogenesis. Cardiomyocyte -specific nuclei were isolated for transcriptomic (RNA-seq) and in vitro assays in H9C2 cells were used to elucidate molecular mechanisms. Results: The HFpEF model successfully exhibited diastolic dysfunction, impaired exercise capacity and cardiac hypertrophy with elevated circulating ketone body concentration. Myocardial metabolomics and snRNA-seq identified a profound metabolic shift characterized by the accumulation of long-chain fatty acids and Krebs cycle intermediates, coupled with the transcriptional downregulation of insulin signaling and fatty acid degradation pathways. Although circulating ketone body level was upregulated, Hmgcs2 ΔiCM mice showed no exacerbation of the HFpEF phenotype. In contrast, Hmgcs2 ΔHep mice exhibited significantly aggravated cardiac hypertrophy (HW/TL; Hmgcs2 flox : 7.41 ± 0.87: Hmgcs2 ΔHep : 8.29 ± 0.73; p = 0.0154). Mechanistically, hepatic ketogenesis was required to maintain circulating beta-hydroxybutyrate (BHB) levels, which directly modulated cardiomyocyte metabolism. BHB acted as a metabolic signal to dampen fatty acid overload and facilitate glucose utilization. Conclusions: Our study identifies a critical "liver-heart axis" where hepatic ketogenesis serves as an essential regulator of myocardial metabolic resilience. Impaired hepatic ketogenesis creates a metabolic mismatch that drives pathological cardiac remodeling. These findings highlight the liver as a therapeutic target within the CKM syndrome framework, suggesting that restoring the hepato-cardiac metabolic bridge may ameliorate HFpEF progression. What is New?: This study identifies a novel liver–adipose–heart axis that governs myocardial metabolic resilience during the development of heart failure with preserved ejection fraction (HFpEF). We demonstrate that while both the liver and heart upregulate ketogenesis under metabolic stress, only hepatic ketogenesis—and not cardiac-intrinsic ketogenesis—is essential for mitigating pathological cardiac remodeling. Mechanistically, liver-derived β -hydroxybutyrate acts as a critical endocrine signal that dampens fatty acid oxidation and facilitates myocardial glucose utilization. What Are the Clinical Implications?: Our findings highlight the liver as a central therapeutic target within the cardiovascular–kidney–metabolic (CKM) syndrome framework, where hepatic metabolic failure directly drives cardiac dysfunction. Restoring the hepato-cardiac metabolic bridge, through either hepatic-targeted therapies or ketone body supplementation, represents a promising strategy to enhance myocardial metabolic flexibility and ameliorate HfpEF in patients with multi-organ metabolic disorders.
- Open Access
- 21 January 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 802, 153332
Nonsteroidal mineralocorticoid receptor antagonist finerenone ameliorates cardiac hypertrophy with increasing glucocorticoid signaling sensitivity
- 21 January 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 802, 153332
Open AccessNonsteroidal mineralocorticoid receptor antagonist finerenone ameliorates cardiac hypertrophy with increasing glucocorticoid signaling sensitivity
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from HTLV-1 bZIP Factor-Induced Reprogramming of Lactate Metabolism and Epigenetic Status Promote Leukemic Cell Expansion
Human cluster 2 genes whose H3K27me3 in TSS's was decreased.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from HTLV-1 bZIP Factor-Induced Reprogramming of Lactate Metabolism and Epigenetic Status Promote Leukemic Cell Expansion
Human cluster 2 genes whose H3K27me3 in TSS's was decreased.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Table S3 from HTLV-1 bZIP Factor-Induced Reprogramming of Lactate Metabolism and Epigenetic Status Promote Leukemic Cell Expansion
Oligonucleotides used in this study.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from HTLV-1 bZIP Factor-Induced Reprogramming of Lactate Metabolism and Epigenetic Status Promote Leukemic Cell Expansion
Oligonucleotides used in this study.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from HTLV-1 bZIP Factor-Induced Reprogramming of Lactate Metabolism and Epigenetic Status Promote Leukemic Cell Expansion
Regulation of TP73 by BATF3 and IRF4.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from HTLV-1 bZIP Factor-Induced Reprogramming of Lactate Metabolism and Epigenetic Status Promote Leukemic Cell Expansion
Regulation of TP73 by BATF3 and IRF4.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from HTLV-1 bZIP Factor-Induced Reprogramming of Lactate Metabolism and Epigenetic Status Promote Leukemic Cell Expansion
Efficacy of the MCT1/4 inhibitor syrosingopine on ATL cells.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from HTLV-1 bZIP Factor-Induced Reprogramming of Lactate Metabolism and Epigenetic Status Promote Leukemic Cell Expansion
Efficacy of the MCT1/4 inhibitor syrosingopine on ATL cells.